Business
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival PRINCETON,
About this update from Cytosorbents Corporation
[{"type":"text","content":"In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival\nPRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, highlights the growing momentum of ex vivo organ perfusion in organ transplantation and the vital role CytoSorb® and ECOS-300CY® are playing in this burgeoning field. In particular, these technologies may help to improve the quality and number of usable organs while improving transplant success rates. Importantly, data from recent peer-reviewed publications highlight how these innovative therapies may improve outcomes in the specific field of lung transplantation. Background – Organ Transplantation, Ex Vivo Organ Perfusion, and CytoSorb/ECOS-300CY Organ transplantation is the gold standard treatment for end-stage organ failure. However, suitable donor organs are scarce and many patients often die waiting for an organ to become available. According to the Global Observatory on Donation and Transplantation, there were approximately 158,000 solid organ transplants in 2022 globally. According to the United Network of Organ Sharing (UNOS) and the European Directorate for the Quality of Medicine and Healthcare (EDQM), in 2022 in the U.S. and E.U. alone, there were approximately an equal number of patients, roughly 153,000, on the transplantation waitlist, primarily due to the lack of suitable organs. Every 10 minutes, someone is added to the waitlist, and roughly every half hour, someone dies on the waiting list, waiting for an organ that never comes. The vast majority of donated organs are from deceased donors, often due to irreversible cardiac or brain death. However, due to a variety of factors, including ischemia and reperfusion injury, cold storage, and the manner by which the donor died, these organs are often damaged with significant inflammation, jeopardizing organ health and importantly the success of the transplantation. In the U.S., according to a 2020 Millman research report, a single lung transplant costs approximately $930,000, a two lung transplant: $1.3 million, a kidney transplant: $443,000, a liver transplant: $878...